Trial · NCT02280655
Adverse Effects of Red Blood Cell Transfusions: A Unifying Hypothesis (Aim 3)
NCT02280655, Phase 2, Completed, Emory University; results first posted 2014-12-04
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Adverse Effects of Red Blood Cell Transfusions: A Unifying Hypothesis (Aim 3). Trials, record NCT02280655. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02280655
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Adverse Effects of Red Blood Cell Transfusions: A Unifying Hypothesis (Aim 3)
- NCT number
- NCT02280655
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 43 participants, actual
- Lead sponsor
- Emory University
- Conditions
- Cardiovascular Diseases
- Interventions
- Storage-aged red blood cells (saRBCs) units, Fresh red blood cells units
- First posted
- 2014-10-31
- Last updated
- 2016-04-11
- Results first posted
- 2014-12-04
- Limitations and caveats
- Only patients receiving routine transfusions were included in the study, thus excluding critically ill/actively bleeding patients requiring emergent transfusions.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Brachial Artery Flow-mediated Dilation (FMD) After Fresh Red Blood Cells (RBCs) Transfusions vs. Storage-aged Red Blood Cells (saRBCs) Transfusions at Baseline | Baseline | Ultrasonography of the brachial artery performed at the bedside using a high-resolution 10-megahertz (MHz) ultrasound transducer before and after suprasystolic inflation of a blood pressure cuff for 5 minutes in the ipsilateral upper arm. Brachial artery FMD was calculated as (hyperemic diameter - baseline diameter)/baseline diameter × 100. |
| Primary | Brachial Artery Flow-mediated Dilation (FMD) After Fresh Red Blood Cells (RBCs) Transfusions vs. Storage-aged Red Blood Cells (saRBCs) Transfusions at 24 Hours After Transfusion | 24 hours after transfusion | Ultrasonography of the brachial artery performed at the bedside using a high-resolution 10-megahertz (MHz) ultrasound transducer before and after suprasystolic inflation of a blood pressure cuff for 5 minutes in the ipsilateral upper arm. Brachial artery FMD was calculated as (hyperemic diameter -24 hour diameter)/24 hour diameter × 100. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Brachial Artery Flow-mediated Dilation (FMD) After Fresh Red Blood Cells (RBCs) Transfusions vs. Storage-aged Red Blood Cells (saRBCs) Transfusions at Baseline | Baseline | percentage of brachial artery diameter | MEAN | |
| PRIMARY | Brachial Artery Flow-mediated Dilation (FMD) After Fresh Red Blood Cells (RBCs) Transfusions vs. Storage-aged Red Blood Cells (saRBCs) Transfusions at 24 Hours After Transfusion | 24 hours after transfusion | percentage of brachial artery diameter | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Brachial Artery Flow-mediated Dilation (FMD) After Fresh Red Blood Cells (RBCs) Transfusions vs. Storage-aged Red Blood Cells (saRBCs) Transfusions at Baseline | Storage-aged Red Blood Cells (saRBCs) | 4.87 | Standard Deviation 5.011 | percentage of brachial artery diameter | |
| Brachial Artery Flow-mediated Dilation (FMD) After Fresh Red Blood Cells (RBCs) Transfusions vs. Storage-aged Red Blood Cells (saRBCs) Transfusions at Baseline | Fresh Red Blood Cells (RBCs) | 5.38 | Standard Deviation 6.5 | percentage of brachial artery diameter | |
| Brachial Artery Flow-mediated Dilation (FMD) After Fresh Red Blood Cells (RBCs) Transfusions vs. Storage-aged Red Blood Cells (saRBCs) Transfusions at 24 Hours After Transfusion | Storage-aged Red Blood Cells (saRBCs) | 2.47 | Standard Deviation 4.88 | percentage of brachial artery diameter | |
| Brachial Artery Flow-mediated Dilation (FMD) After Fresh Red Blood Cells (RBCs) Transfusions vs. Storage-aged Red Blood Cells (saRBCs) Transfusions at 24 Hours After Transfusion | Fresh Red Blood Cells (RBCs) | 4.7 | Standard Deviation 6.19 | percentage of brachial artery diameter |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Storage-aged Red Blood Cells (saRBCs) | 25 | |
| Overall Study | STARTED | Fresh Red Blood Cells (RBCs) | 18 | |
| Overall Study | COMPLETED | Storage-aged Red Blood Cells (saRBCs) | 25 | |
| Overall Study | COMPLETED | Fresh Red Blood Cells (RBCs) | 18 | |
| Overall Study | NOT COMPLETED | Storage-aged Red Blood Cells (saRBCs) | 0 | |
| Overall Study | NOT COMPLETED | Fresh Red Blood Cells (RBCs) | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Storage-aged Red Blood Cells (saRBCs) | ||
| Total, all-cause mortality | Fresh Red Blood Cells (RBCs) | ||
| Total, other adverse events | Storage-aged Red Blood Cells (saRBCs) | 0 | 25 |
| Total, other adverse events | Fresh Red Blood Cells (RBCs) | 0 | 18 |
| Total, serious adverse events | Storage-aged Red Blood Cells (saRBCs) | 0 | 25 |
| Total, serious adverse events | Fresh Red Blood Cells (RBCs) | 0 | 18 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Storage-aged Red Blood Cells (saRBCs) vs Fresh Red Blood Cells (RBCs): serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02280655
GET https://conductscience.org/api/trials/v1/NCT02280655/registered